TY  - JOUR
AU  - Gonzalez-Alvaro, Isidoro
AU  - Blasco, Antonio J.
AU  - Lazaro, Pablo
AU  - Sanchez-Piedra, Carlos
AU  - Almodovar, Raquel
AU  - Bachiller-Corral, Javier
AU  - Balsa, Alejandro
AU  - Caliz, Rafael
AU  - Candelas, Gloria
AU  - Fernandez-Carballido, Cristina
AU  - Garcia-Aparicio, Angel
AU  - Garcia-Magallon, Blanca
AU  - Garcia-Vicuna, Rosario
AU  - Gomez-Centeno, Antonio
AU  - Ortiz, Ana M.
AU  - Sanmarti, Raimon
AU  - Sanz, Jesus
AU  - Tejera, Beatriz
PY  - 2017
DO  - 10.1016/j.heliyon.2017.e00452
SN  - 2405-8440
UR  - http://hdl.handle.net/10668/18793
T2  - Heliyon
AB  - Background: Reducing the dose of biological therapy (BT) when patients with immune-mediated arthritis achieve a sustained therapeutic goal may help to decrease costs for national health services and reduce the risk of serious infection. However, there...
LA  - en
PB  - Elsevier sci ltd
KW  - Pharmaceutical science
KW  - Evidence-based medicine
KW  - Medicine
KW  - Low disease-activity
KW  - Ankylosing-spondylitis
KW  - Long-term
KW  - Appropriateness method
KW  - Psoriatic-arthritis
KW  - Clinical-practice
KW  - Metaanalysis
KW  - Remission
KW  - Efficacy
KW  - Safety
TI  - REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients
TY  - research article
VL  - 3
ER  -